Compare Stocks: CING, TTRX, AMRN, and ZNTL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63	$14.39	$12.96 ▼ $20.90	$287.87M	0.76	82,890 shs	80,472 shs
CING Cingulate	$5.10	$5.06	$3.16 ▼ $11.89	$74.15M	-0.88	144,472 shs	106,975 shs
TTRX Turn Therapeutics	$9.80	$9.17	$2.57 ▼ $26.50	$291.92M	N/A	54,046 shs	70,574 shs
ZNTL Zentalis Pharmaceuticals	$3.99	$4.37	$1.21 ▼ $6.95	$285.96M	1.85	1.11 million shs	997,785 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	0.00%	-2.43%	-5.08%	-4.01%	-11.09%
CING Cingulate	0.00%	-4.14%	-4.49%	+12.58%	+30.77%
TTRX Turn Therapeutics	0.00%	-0.41%	-5.86%	+83.86%	+979,999,900.00%
ZNTL Zentalis Pharmaceuticals	0.00%	+5.00%	-5.45%	+11.45%	+128.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63	$14.39	$12.96 ▼ $20.90	$287.87M	0.76	82,890 shs	80,472 shs
CING Cingulate	$5.10	$5.06	$3.16 ▼ $11.89	$74.15M	-0.88	144,472 shs	106,975 shs
TTRX Turn Therapeutics	$9.80	$9.17	$2.57 ▼ $26.50	$291.92M	N/A	54,046 shs	70,574 shs
ZNTL Zentalis Pharmaceuticals	$3.99	$4.37	$1.21 ▼ $6.95	$285.96M	1.85	1.11 million shs	997,785 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	0.00%	-2.43%	-5.08%	-4.01%	-11.09%
CING Cingulate	0.00%	-4.14%	-4.49%	+12.58%	+30.77%
TTRX Turn Therapeutics	0.00%	-0.41%	-5.86%	+83.86%	+979,999,900.00%
ZNTL Zentalis Pharmaceuticals	0.00%	+5.00%	-5.45%	+11.45%	+128.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.33	Sell	$13.00	-4.62% Downside
CING Cingulate	2.50	Moderate Buy	$27.00	429.41% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$8.00	-18.37% Downside
ZNTL Zentalis Pharmaceuticals	2.33	Hold	$6.75	69.17% Upside

Current Analyst Ratings Breakdown

Latest CING, TTRX, AMRN, and ZNTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/23/2026	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$10.00 ➝ $9.00
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/18/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/24/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/21/2026	TTRX Turn Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/20/2026	TTRX Turn Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	AMRN Amarin	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$213.65M	1.35	$0.36 per share	37.76	$22.07 per share	0.62
CING Cingulate	N/A	N/A	N/A	N/A	$0.31 per share	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.16 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	4.24	N/A	N/A	$2.99 per share	1.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
CING Cingulate	-$22.45M	-$3.59	N/A	N/A	N/A	N/A	-238.40%	-128.67%	11/12/2026 (Estimated)
TTRX Turn Therapeutics	-$3.19M	-$0.29	N/A	N/A	N/A	N/A	-230.84%	-53.19%	N/A
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest CING, TTRX, AMRN, and ZNTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CING Cingulate	-$0.63	-$0.45	+$0.18	-$0.45	$0.17 million	N/A
8/12/2026	Q2 2026	TTRX Turn Therapeutics	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.67	2.67
CING Cingulate	N/A	3.50	3.50
TTRX Turn Therapeutics	8.83	1.19	1.19
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
CING Cingulate	41.31%
TTRX Turn Therapeutics	N/A
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMRN Amarin	4.21%
CING Cingulate	5.30%
TTRX Turn Therapeutics	N/A
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	21.12 million	20.23 million	Optionable
CING Cingulate	20	14.54 million	13.77 million	Not Optionable
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A
ZNTL Zentalis Pharmaceuticals	160	71.67 million	68.95 million	Optionable

CING, TTRX, AMRN, and ZNTL Headlines

Recent News About These Companies

BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

September 4 at 3:28 AM | marketbeat.com

Zentalis to present at Wells Fargo, Morgan Stanley events

September 2, 2026 | msn.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

August 31, 2026 | seekingalpha.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

August 29, 2026 | marketbeat.com

Primecap Management Co. CA Takes $4.64 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 27, 2026 | marketbeat.com

652,750 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

3,947,913 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by 5AM Venture Management LLC

August 26, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 Shares

August 20, 2026 | insidertrades.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

August 19, 2026 | marketbeat.com

Zentalis Pharma closes $92.6 million public offering

August 19, 2026 | thepharmaletter.comT

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026 | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17, 2026 | globenewswire.com

GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

August 17, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

August 16, 2026 | marketbeat.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

August 14, 2026 | msn.com

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

August 13, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

August 13, 2026 | globenewswire.com

HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CING, TTRX, AMRN, and ZNTL Company Descriptions

Amarin NASDAQ:AMRN

$13.63 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Cingulate NASDAQ:CING

$5.10 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Turn Therapeutics NASDAQ:TTRX

$9.80 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$3.99 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CING, TTRX, AMRN, and ZNTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CING, TTRX, AMRN, and ZNTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CING, TTRX, AMRN, and ZNTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CING, TTRX, AMRN, and ZNTL Company Descriptions

Amarin NASDAQ:AMRN

Cingulate NASDAQ:CING

Turn Therapeutics NASDAQ:TTRX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CING, TTRX, AMRN, and ZNTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CING, TTRX, AMRN, and ZNTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CING, TTRX, AMRN, and ZNTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CING, TTRX, AMRN, and ZNTL Company Descriptions

Amarin NASDAQ:AMRN

Cingulate NASDAQ:CING

Turn Therapeutics NASDAQ:TTRX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools